Bronchiolitis obliterans after stem-cell transplant: causes and new treatments
Official title: Bronchiolitis Obliterans: Discovery and Therapy
Funded at Dana-Farber Cancer Inst · NIH-11174489 · Data updated 2026-11-12
This project tries a new drug called KD025 (a ROCK2 blocker) to help people who develop bronchiolitis obliterans after an allogeneic stem-cell transplant.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 15, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $647,464 |
| NIH project number | 5P01HL158505-04 |
| Project ID | NIH-11174489 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people who have bronchiolitis obliterans syndrome after an allogeneic hematopoietic cell (stem-cell) transplant.
✕Less likely to help
People without transplant-related BOS, those with other unrelated lung diseases, or those with very advanced, irreversible lung damage may not benefit from this treatment.
What this research studies
You would be offered a clinical treatment with KD025 aimed at the lung problems that happen after an allogeneic transplant. At the same time, researchers will grow human lung organoids and use immunogenomic tests to find which airway cells and antigens are being attacked. Insights from mouse models will guide which patients and doses might work best. The combined lab and clinical work aims to reduce airway fibrosis and improve breathing and survival.
Why it matters
Potential benefit: If successful, this could slow or reverse lung scarring, improve breathing, and raise survival for people with post-transplant BOS.
How similar studies have gone: KD025 has shown promising activity for chronic graft-versus-host disease in prior work, but using it specifically to treat BOS is a new application being tested here.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Cutler, Corey S — Dana-Farber Cancer Inst
- Study coordinator: Cutler, Corey S
Related research
Other NIH-funded projects on the same topics.
-
Airway basal cell stress and environmentally caused bronchiolitis obliterans
Researchers are studying how certain inhaled chemicals may damage the airway’s foundational cells and lead to a serious lung disease called bronchiolitis obliterans.
-
Bronchiolitis Obliterans: turning biology insights into potential therapy
A potential new therapy for a serious lung disease that can occur after stem cell transplant is being tested to see if it can reverse damage and improve breathing.
-
Interrupting harmful lung cell interactions to reduce fluid leakage in critically ill children with bronchiolitis
AYA pediatric patients with bronchiolitis who are severely ill may benefit from a study that targets lung cell signals to lessen fluid leak and improve breathing.
-
Airway stem cell problems in transplant-related obliterative bronchiolitis
This work looks at how airway stem cells change after lung transplant to help people who develop obliterative bronchiolitis.
-
Lymphatic changes after lung transplant and risk of bronchiolitis obliterans
Researchers are looking at how damage or repair of the lung's lymphatic vessels after transplant affects the chance of developing bronchiolitis obliterans in people who receive lung transplants.
-
How respiratory viruses affect long-term lung damage after donor stem cell transplant
Following people who had donor stem cell transplants to see how common respiratory viruses relate to long-term lung damage called bronchiolitis obliterans syndrome.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.